Parsatuzumab
Based on 1 Customer Validation
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 97.40%
- CAS No.: 1312797-14-0
- Masse moléculaire:148.22 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform VEGFR
More
Activité biologique
Human IgG1 kappa
Human
EGFL7
EGFL7 is a vascular-restricted extracellular matrix protein that promotes endothelial cell adhesion and survival[1].
Parsatuzumab (48 h) inhibits cell proliferation and increases apoptosis against patient-derived xenograft (PDX) cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Patient-derived xenograft (PDX) cells
-
Concentration:/
-
Incubation Time:48 hours
-
Result:Inhibited cell proliferation by 70% from 20%, and resulted in apoptosis increases by 67-87% from 8-17%.
Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7 and inhibits mantle cell lymphoma (MCL) cell growth and prolongs survival in mouse models of MCL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG mice injected with Rec1 cells (s.c.)[2]
-
Dosage:50 mg/kg
-
Administration:Intravenous injection; 3 times per week; sacrificed mice when tumor reached end point criteria
-
Result:Significantly decreased tumor volume than IgG and increased survival of mice.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized EGFL7/VE-Statin Protein, Human can bind Parsatuzumab. The EC50 for this effect is 12.19 ng/mL.
Chemical Information
-
CAS No. 1312797-14-0
-
Appearance Liquid
-
Masse moléculaire 148.22 kDa
-
Color Colorless to light yellow
-
SMILES
[Parsatuzumab]
-
Synonyms
Anti-EGFL7; RG 7414
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Parsatuzumab Related Classifications
HY-P99215 Related Classifications
Powered by Bioz